Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M |
| Cost of Revenue | 24.45M | 18.12M | 9.07M | 4.51M | 3.45M |
| Gross Profit | 296.64M | 269.15M | 203.74M | 132.74M | 99.88M |
| SG&A Expenses | 239.98M | 209.12M | 196.86M | 167.88M | 141.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 380.69M | 401.24M | 260.00M | 216.56M | 170.32M |
| Operating Income | -59.61M | -113.98M | -47.20M | -79.31M | -67.00M |
| Income Before Tax | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.58M | -114.19M | -42.28M | -73.24M | -59.42M |
| EBIT | -59.61M | -113.98M | -47.20M | -79.31M | -67.00M |
| EBITDA | -59.22M | -113.62M | -46.83M | -78.93M | -66.63M |
| EPS Basic | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 |
| Normalized Basic EPS | -1.60 | -3.10 | -1.19 | -2.07 | -1.69 |
| EPS Diluted | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 |
| Normalized Diluted EPS | -1.60 | -3.10 | -1.19 | -2.07 | -1.69 |
| Average Basic Shares Outstanding | 22.83M | 22.48M | 22.21M | 22.09M | 21.93M |
| Average Diluted Shares Outstanding | 22.83M | 22.48M | 22.21M | 22.09M | 21.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |